Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

4.86
+0.34007.52%
Post-market: 4.950.0900+1.85%19:48 EDT
Volume:71.13K
Turnover:348.06K
Market Cap:7.93M
PE:-0.26
High:5.20
Open:4.53
Low:4.53
Close:4.52
52wk High:71.50
52wk Low:3.18
Shares:1.63M
Float Shares:1.22M
Volume Ratio:2.26
T/O Rate:5.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:2.48
PE(LYR):-0.09

Loading ...

Press Release: Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Dow Jones
·
Aug 10

Ernexa Therapeutics Inc Expected to Post a Loss of $3.84 a Share - Earnings Preview

Reuters
·
Aug 08

Ernexa Q2 Net Loss Widens to $4.01 Million; Reports no Revenue

Reuters
·
Aug 07

Ernexa CEO Says Erna-101 Aims to Boost Combination Immunotherapy in Solid Tumors

Reuters
·
Jul 24

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

GlobeNewswire
·
Jul 24

NASDAQ Trade Halt Volatility Trading Pause at 09:39 Am

Reuters
·
Jul 15

Ernexa Therapeutics announces new ERNA-101 preclinical data

TIPRANKS
·
Jul 15

Ernexa Says Erna-101 Plus Anti-pd-1 Clears Tumors in Ovarian Cancer Preclinical Study

Reuters
·
Jul 15

Ernexa Therapeutics - on Track for Ind Submission Q3 2026 and Phase 1 Trial Q4 2026

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics - Plans Ind Submission for Q3 2026; Phase 1 Trial Expected to Begin Q4 2026

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics - no Complete Tumor Clearance Observed with Erna-101 or Anti-pd-1 Monotherapy

THOMSON REUTERS
·
Jul 15

Ernexa Therapeutics CEO Corner Highlights Differentiated Erna-101 Platform as Company Advances Toward Planned First-in-human Phase 1 Study in 2026

THOMSON REUTERS
·
Jul 14

Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026

GlobeNewswire
·
Jul 14

Ernexa Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Jul 03

Ernexa Therapeutics SVP of Finance Sandra Gurrola Resigns Effective July 3

Reuters
·
Jun 27

Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients

GlobeNewswire
·
Jun 25

Ernexa expects FDA review of ERNA-101 IND in Q4 2026

Reuters
·
Jun 17

Ernexa Therapeutics - Plans Ind Submission for Erna-101 in Q3 2026 and Phase 1 Study in Q4 2026

THOMSON REUTERS
·
Jun 17

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

GlobeNewswire
·
Jun 17

Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer

GlobeNewswire
·
Jun 09